Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2012 |
Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents
These laboratory trial studies the development and treatment of a mouse model for acute
myeloid leukemia (AML) using samples from younger patients with AML. Studying tissue samples
from patients with cancer in the laboratory may help doctors learn more about cancer and how
well patients will respond to treatment.
myeloid leukemia (AML) using samples from younger patients with AML. Studying tissue samples
from patients with cancer in the laboratory may help doctors learn more about cancer and how
well patients will respond to treatment.
PRIMARY OBJECTIVES:
I. To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3
(FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD scid
gamma (NSG) mice.
II. To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase
inhibitors.
OUTLINE:
Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with
sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue
samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and
CD33+ cells by quantitative flow cytometry.
I. To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3
(FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD scid
gamma (NSG) mice.
II. To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase
inhibitors.
OUTLINE:
Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with
sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue
samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and
CD33+ cells by quantitative flow cytometry.
Inclusion Criteria:
- Cryopreserved human AML samples
- FLT3-ITD samples with high allelic ratios
We found this trial at
1
site
Monrovia, California 91016
Principal Investigator: Sarah K. Tasian, MD
Phone: 877-827-3222
Click here to add this to my saved trials
